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ABSTRACT 
Objective: The current research work focus to simple and rugged bioanalytical method development and validation of brivudine in human plasma 
using high-performance liquid chromatography. 
Methods: The analyte (Brivudine) and internal standard (Sofosbuvir) were extracted using the Solid Phase Extraction (SPE) technique. The 
chromatographic separation was accomplished by using Zorbax eclipse XDB-C18 Column (150×4.6 mm, 5 μm) with a mobile phase consisted of 
Methanol: 0.5% Ortho-phosphoric acid (65:35%, v/v) respectively, at a flow rate of 0.7 mL/min. The developed method was validated by 
performing system suitability, carryover effect, linearity, selectivity, sensitivity, precision, accuracy, recovery, ruggedness, and stability studies. The 
method was validated as per USFDA guidelines. 
Results: The selected chromatographic condition was found to efficiently separated brivudine (RT-3.55 min) and ISTD (RT-7.87 min). The assay 
demonstrated a linear dynamic range of 85.205 to 4500.246 ng/ml for brivudine in human plasma with r2>0.99. Demonstrated the lowest limit of 
detection at 85.205 ng/ml. This method established an intra-run and inter-run precision within the range of 2.99-6.31%CV and 3.67-5.80%CV, 
respectively. Additional intra-run and inter-run accuracy were within the range of 97.55-105.37% and 99.27-102.15%, respectively. The mean 
percentage recovery of brivudine and ISTD studies proved good extraction efficiency and the robustness was also evaluated.  
Conclusion: A simple, accurate, precise, linear and rugged RP-HPLC method was developed and validated for the estimation of brivudine in human 
plasma with K2EDTA anticoagulant and suitable for conducting BA/BE and TDM. 
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INTRODUCTION 
It is available as a 125 mg tablet and as a 0.1% ointment Brivudine is 
a strong antiviral agent against the varicella-zoster virus and it is an 
analog of thymidine. It blocks viral replication by interfering with 
viral DNA through inhibition of deoxythymidine dehydrogenase. It is 
almost completely absorbed in the gastrointestinal tract after oral 
administration, but due to extensive first-pass metabolism, 
bioavailability is about 30% and extensively bound to plasma 
proteins (95% binding), but is not displaced by concomitant drugs, 
including analgesics, cardiac glycosides, cytostatics and virostatics 
and excreted mainly in the urine (65%) with Less than 1% of 
unchanged brivudine found in urine, a minor fraction has been 
found in the faeces (21%). The terminal half-life has been 
established at 16 h [1].  
nt for ophthalmologic use [2]. It is also used as eye drops for the 
treatment of HSV-1 epithelial keratitis [3]. Oral brivudin is now 
approved in several EU countries (Germany, Italy, Austria, Belgium, 
Luxembourg, Spain, Portugal and Greece) for the treatment of 
herpes zoster in immune-competent patients with the dose regimen 
of one tablet (125 mg) per day for 7 d [4].  
This is expected to work by blocking the activity of a protein called 
‘heat shock protein 27 (Hsp27), which is found in high amounts in 
pancreatic cancer cells. Hsp27 is known to play a key role in 
‘chemoresistance’. When brivudine is given together with other 
anticancer medicines, it is expected to prevent the cancers cells from 
developing resistance to the medicines, helping to treat the disease [5].  
Systematic (IUPAC) name: 5-[(1E)-2-bromoethenyl]-1-[(2R, 4S, 5R)-
4-hydroxy-5-hydroxymethyl) oxolan-2-yl]-1,2,3,4-tetrahydro-
pyrimidine-2,4-dione (fig. 1). It is freely soluble in Methanol and 
chemical formula is C11H13BrN2O5 with the molecular weight 
333.135 g/mol [6].  
 
Fig. 1: Chemical structure of brivudine 
 
Drug literature review reveals that few analytical quantification 
methods have been reported for the brivudine in bulk, formulations, 
and biological matrices. Which includes UV spectrophotometric [8], 
capillary electrophoresis [9,10], high performance liquid 
chromatography coupled with ultraviolet (UV) detection [11, 12] 
and ultra-high performance liquid chromatography-tandem mass 
spectrometric detection (UPLC-MS/MS) [13]. The present work 
designed to develop a simple, rugged, economic and validated RP-
HPLC method for the determination of brivudine in human plasma 
with anti-coagulant K2EDTA. 
MATERIALS AND METHODS 
Chemicals and reagents 
Brivudine and sofosbuvir bulk drugs were kindly provided as a gift 
sample by Sequent Labs Pvt. Ltd., Mangalore, India. Analytical grade 
of ammonium acetate purchased from Rankem Ltd., India and HPLC 
grade of methanol and acetonitrile purchased from Merck 
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Specialties Private Limited, India. Analytical grade orthophosphoric 
acid purchased from Rankem Ltd., India, Matrix: Human plasma 
(K2EDTA-Anticoagulant) acquired from a registered blood bank. 
Instrument 
Quantitative HPLC was performed on a Shimadzu HPLC system with 
PDA detector and LC-MS solution software. An agilent Zorbax 
Eclipse XDB-C18 column of 250 mm X 4.6 mm: i. d and 5μm particle 
size with 300 °A pore size was used. Micro Weighing Balance (MX5)-
Mettler Toledo, an Ultrasonic bath sonicator, Deep Freezer (-20±5 
°C)-Thermo Fisher Scientific, Refrigerator (2-8 °C)-Thermo Fisher 
Scientific and Vortex-Spinix, Heidolph top were used in the study. 
Chromatographic condition 
Chromatography separation was achieved on a reverse-phase 
zorbax eclipse XDB-C18 column (250×4.6 mm, 5 μm) with isocratic 
elution by methanol: 0.5% O-phosphoric acid (65:35%, v/v) as the 
mobile phase. Chromatographic peaks were resolved by the mobile 
phase with a flow rate of 0.7 ml/min. The total analysis run time of 
10 min and the analytical column temperature ambient. 
Standard solution preparation 
Accurately weighed and transferred 5 mg of Brivudine into 5 ml 
volumetric flask. The solution is made up to the mark by using Methanol 
diluent to get the concentration of 1.0 mg/ml and stored at 2-8 ᵒC. 
Working standard preparation 
The working solutions for the calibration standards containing 
brivudine were prepared by dilution of the stock solution with the 
diluent 60% methanol solution (v/v). Calibration standards in 
human plasma were prepared by diluting the corresponding 
working solutions with screened blank plasma samples at the 
following concentrations: 85.205, 170.411, 340.141, 583.232, 
972.053, 1620.088, 2700.147 and 4500.246 ng/ml for brivudine. 
The working solutions for the quality control (QC) samples were 
prepared at the following concentrations: 85.211, 240.030, 
1500.188, 3500.204 and 17501.022 ng/ml for brivudine. ISTD 
working standard solution at a concentration of 500 ng/ml was 
prepared by diluting the stock solution (1.0 mg/ml) with the diluent. 
All stock solutions, working solutions, calibration standards and QCs 
were immediately stored at 2-8 ᵒC. 
Sample preparation 
Exactly 0.200 ml of plasma sample was aliquoted and transferred 
into a tarsons ria vial polypropylene tube and 0.050 ml of ISTD 
(500ng/ml) working concentration solution was added, except for 
standard blank, to which 0.050 ml of 60% methanol solution (v/v) 
was added and vortexed. To this 0.250 ml of 50 mmol ammonium 
acetate (w/v) was added and vortexed. Sample clean-up was 
conducted by using the following Solid Phase Extraction procedure, 
the waters cartridges (Oasis HLB) were first conditioned with 
methanol 1 ml to activate the chemical bonds then equilibrated by 
using water 1 ml, in a positive pressure manifold SPE. Plasma 
samples were loaded onto SPE cartridges. Then, the cartridges were 
washed with water 1 ml twice and followed by 5% methanol 
solution (v/v) 1 ml to wash the interferences and the analyte was 
successively eluted with 0.250 ml of 100% methanol with elution 
tarsons ria vial polypropylene tube contained 0.050 ml of 0.5% 
orthophosphoric acid solution (v/v).  
Method validation 
Method validation was done as per the criteria of industrial guidance 
for the bioanalytical method validation of USFDA [14-16]. 
System suitability 
System suitability experiment was performed by injecting six 
repeated injections using a standard aqueous mixture equivalent to 
an approximately middle concentration of the calibration curve of 
brivudine and working concentration of ISTD during the start of the 
method validation and at the start of the respective day. The Area 
ratio of system suitability has within the acceptance limits of 5% CV. 
Carryover effect 
Carryover effect was performed in order to eliminate the carryover 
from the previous injection to the next injection. Extracted blank, 
extracted LLOQ, and extracted ULOQ samples were prepared from 
same biological matrix lot. These samples were injected in the order of 
mobile phase, extracted blank plasma, extracted LLOQ, extracted 
ULOQ and extracted blank plasma samples during the start of the 
method validation. The response of interfering peaks at the retention 
time of analyte has ≤ 20% of the response of extracted LLOQ and at the 
retention time of ISTD have ≤ 5% of response of extracted LLOQ. 
Selectivity/Sensitivity 
The selectivity of the method was assessed by analysing human 
blank plasma samples as of different healthy human volunteer’s six 
lots from a normal plasma source, two lots from lipemic source and 
two lots from haemolysed source, to investigate the potential 
interferences of endogenous compounds at the LC peak region for 
brivudine and ISTD. The sensitivity of the method was determined 
with the LLOQ level of the analyte with PandA. The peak area of 
LLOQ for brivudine and ISTD at corresponding retention time in 
blank samples should not be more than 20% and 5% of the mean 
peak area of sofosbuvir. 
Linearity 
Linearity of the plasma samples was quantified using the peak-area 
ratio versus analyte nominal concentration. A calibration curve was 
constructed using linear regression and it consists of a standard 
blank sample, a standard Zero sample (Blank sample+ISTD) and 
eight non-zero samples which are distributed throughout the 
calibration range 85.205–4500.246 ng/ml of brivudine. The 
acceptance limit for a calibration curve was a correlation coefficient 
(r2) of 0.98 or Greeter, and each back-calculated standard 
concentration should be±15% deviation from the nominal value 
except LLOQ, which was set at±20%. 
Precision and accuracy 
Precision and Accuracy batch was assessed by analyzing three 
batches. For P and A studies five concentration QC samples were 
prepared as (LLOQ) Lower Limit of Quantification, (LQC) Lower 
Quality Control, (MQC) Medium Quality Control, (HQC) High-Quality 
Control and (DIQC) Dilution Integrated Quality Control 
corresponding to 85.211, 240.030, 1500.188, 3500.204 and 
17501.022ng/ml respectively, with six replicates each. The intra-run 
and inter-run precision (% CV) for LOQ, MQC, HQC and DIQC should 
be ≤ 15% except for LLOQ, which was set at ≤20% and the intra-run 
and inter-run accuracy for LOQ, MQC, HQC and DIQC should be 
within±15% except for LLOQ, which was set at within±20%. 
Recovery  
The percentage recovery of brivudine from human plasma was 
determined by comparing the mean peak area of six extracted LQC, 
MQC and HQC (240.030, 1500.188, and 3500.204 ng/ml) 
respectively, quality control samples to the mean peak area of six 
post-extracted LQC, MQC and HQC quality control samples with the 
same concentrations. 
The percentage recovery of ISTD from human plasma was 
determined by comparing the mean peak area of the prepared 
extracted ISTD to the mean peak area of Post extracted ISTD at the 
concentration level intended for use. 
% recovery of ISTD has to be less than 110%. 
Dilution integrity 
Dilution integrity was assessed to ensure that samples could be 
diluted with a screened blank matrix without affecting the final 
concentration. Brivudine spiked human plasma samples were 
prepared at concentrations of 17501.022 ng/ml, above the upper 
limit of the calibration range. These solutions were further diluted 
with human pooled plasma five times dilution in six replicates and 
analysed with PandA parameters. The six replicates have a precision 
of ≤ 15% CV and accuracy of 100±15%. 
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Ruggedness 
The ruggedness of the method was studied by changing the 
experimental condition with a precision and accuracy batch. The 
batch was monitored using a similar type column of another 
manufacture (Phenomenex Luna C18) and different analyst in the 
same laboratory. 
Stability experiments 
The stability was calculated by analysing quality control samples 
and comparing the found concentration to the nominal 
concentration values. 
Stock solution stability 
The aqueous stock solutions were prepared and kept at 2-8 °C for 44 
d. The mean peak response of the stored stock solution of analyte 
and ISTD versus the comparable freshly prepared stock solution and 
immediately analysed.  
Bench-top stability 
Stability of analyte was analysed in the plasma after 8h 30 min at 
room temperature was determined with six replicates of quality 
control samples at LQC and HQC concentration levels. 
Freeze-thaw stability 
Six replicates of stability quality control samples (LQC and HQC) 
were stored in the deep freezer at-20 °C. Thawed at room 
temperature, followed by freezing for minimum 12hr. The QC 
samples were subjected to five freeze-thaw cycles before being 
extracted and analysed. 
Auto-sampler stability 
Six replicates of stability quality control samples (LQC and HQC) 
were processed and left in the auto-sampler rack for 16 h 30 min at 
4 °C and then injected and quantified. 
Wet extract stability 
Six replicates of stability quality control samples (LQC and HQC) 
were processed and stored in wet extract form at 2-8 °C in the 
refrigerator for 24h. 
Long-term plasma stability 
For long term stability, three sets of quality control samples 
(LQC, HQC and DIQC) were stored in the deep freezer at-20 °C 
for 44 d. The Stability plasma samples were extracted and 
analysed using freshly prepared calibration standards and run 
acceptance QC’s.  
All stability parameters were considered to be stable if assay values 
were within the acceptable tolerance of accuracy (i. e±15% Bias) 
and precision (i. e ≤15%CV). 
RESULTS AND DISCUSSION 
System suitability 
The system suitability %CV of the retention time was found to be 
0.41-1.55% for the analyte and 0.33-2.61% for ISTD. The % CV of 
the peak area ratio was found to be 2.33-4.10%. The results were 
found to be within tolerance and are presented in table 1. 
Carryover effect 
The result observed that no carryover was found during this method 
for both analyte and ISTD and it does not affect the precision and 
accuracy. The result was summarized in table 2. 
Selectivity/sensitivity 
The selectivity of the method was demonstrated on ten blank plasma 
samples obtained from different lots. The chromatograms were 
found to be free from significant endogenous interferences. These 
batches were further selected for the preparation of standard CC and 
QC samples and the % bias of LLOQ samples was within the 
acceptable range of±20%. 
Linearity 
The linearity of the method was demonstrated for brivudine in the 
concentration range of 85.205-4500.246 ng/ml) fig. 4 at eight non-
zero sample points. The correlation coefficients (r2) for the standard 
curves ranged from 0.9989 to 0.9997 for brivudine. The result was 
summarized in table 3. 
Precision and accuracy 
The intra-run and inter-run accuracy for each concentration level 
was within the range of 97.55-105.37% and 99.27-102.15%, 
respectively, and the intra-run and inter-run precision for each 
concentration level within the range of 2.99-6.31 %CV and 3.67-5.80 
% CV, respectively. The intra-run and inter-run precision and 
accuracy of the method are presented in table 4. 
Recovery 
The mean % recovery for LQC, MQC and HQC samples of brivudine 
were found to be 78.74%, 74.08% and 67.50% respectively. The 
mean % overall recovery of analyte was found to be 73.44% with 
acceptable precision of 7.69% CV and the ISTD % mean recovery 
was found to be 69.73% at MQC level. The result was summarized in 
table 5. 
Dilution integrity  
Dilution integrity of brivudine was performed and evaluated. The 
percentage nominal was found within the limit of ±15% and the 
estimated precision was ≤ 15% and an accuracy of 100±15%. It 
shows that the drug can be diluted to five times and the results will 
be reproducible and are presented in table 4. 
Ruggedness  
The current method indicated good ruggedness when it is 
performed by using different analyst and different columns. The 
results of the ruggedness were found to be within the acceptance 
limit and are presented in table 6. 
Stability 
The % bias of stock solutions stability was tested for analyte and 
ISTD and established under refrigerator condition 2-8 °C for 44 d 
and results were found to be within the range of ±10%. The analyte 
passed all stability parameter tests viz., Auto-sampler (16 h 30 min), 
Bench-top (8h 30 min), wet extract (24h), Freeze-Thaw (5 cycles) 
and deep freezer stability at-20 °C for at least 44 d. There was no 
significant decrease in the analyte concentration was observed with 
a good percentage of accuracy and precision for stability quality 
control samples. The summary of the stability parameter for 
brivudine presented in table 7. 
The developed chromatographic method for the quantification of 
brivudine in human plasma was simple, reproducible and 
economical, as exposed by the statistical data of analysis. The 
internal standard used is readily available. The mobile phase is 
simple to prepare and cost-effective. The analytical assay of 
brivudine was completed within 10.0 min, revealing the rapidity of 
the proposed RP-HPLC method. The linearity results showed that an 
excellent correlation existed between peak area and concentration 
of brivudine within the concentration range tested. The values of 
slope and intercept of the calibration graph indicated the good 
reproducibility of the proposed method. Higher values of correlation 
coefficient validated the linearity of the calibration plot. PandA 
results over three analytical batches are meeting the acceptance 
criteria. Overall percentage mean recovery is 73.44%. The overall 
mean recovery % CV for three QC levels less than 15.00 %. Recovery 
statistical data was found to be within limits. Brivudine was found to 
be stable as long term shock at-20 °C for 44 d. When compared to 
previous bio-analytical methods [9-13], the developed method was 
simple, economical and accurate bio-HPLC method in human 
plasma. 
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Table 1: System suitability 
S. No. Brivudine (Analyte) Sofosbuvir (ISTD) Area ratio 
Retention time (min) Retention time (min) 
1 3.57 7.88 0.3144 
2 3.52 7.80 0.3230 
3 3.55 7.91 0.2944 
4 3.56 7.85 0.2975 
5 3.58 7.92 0.3142 
6 3.51 7.85 0.3003 
mean±SD 3.55 7.87 0.3073 
±SD 0.0279 0.0445 0.0115 
%CV 0.79 0.57 3.74 
*Number of injections-6 
  
Table 2: Carry over effect 
Sample name Analyte area % Carryover (analyte) ISTD area % Carryover (ISTD) 
Briv-Mobile Phase 0 0.00 0 0.00 
Briv-Extracted Blank 0 0.00 0 0.00 
Briv-Extracted LLOQ 3251 N/AP 184527 N/AP 
Briv-Extracted ULOQ 159468 N/AP 176238 N/AP 
Briv-Extracted Blank 0 0.00 0 0.00 
 
Table 3: Linearity 
STD ID STD 1 STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 STD 8 
Nominal concentration (ng/ml) 85.205 170.411 340.141 583.232 972.053 1620.088 2700.147 4500.246 
n 3 3 3 3 3 3 3 3 
mean±SD 85.798 164.098 355.289 612.077 973.657 1688.178 2851.115 4627.626 
±SD 3.33 3.61 7.15 16.91 55.09 86.55 102.07 138.22 
%CV 3.88 2.20 2.01 2.76 5.66 5.13 3.58 2.99 
% Accuracy 100.70 96.30 104.45 104.95 100.17 104.20 105.59 102.83 
*Number of each concentration injections-3 
 













n 6 6 6 6 6 
Intra-run mean±SD 87.170 235.249 1580.80 3560.44 18271.84 
Intra-run±SD 4.30 7.02 96.71 176.53 1152.36 
Intra-run %CV 4.94 2.99 6.12 4.96 6.31 
Intra-run % Accuracy 102.30 98.01 105.37 101.72 104.40 
n 6 6 6 6 6 
Intra-run mean±SD 85.704 234.159 1525.753 3475.642 17965.238 
Intra-run±SD 4.82 7.40 58.86 210.38 937.67 
Intra-run %CV 5.62 3.16 3.86 6.05 5.22 
Intra-run % Accuracy 100.58 97.55 101.70 99.30 102.65 
n 6 6 6 6 6 
Intra-run mean±SD 88.268 245.448 1488.788 3430.830 17299.037 
Intra-run±SD 4.38 9.38 93.65 134.80 834.32 
Intra-run %CV 4.97 3.82 6.29 3.93 4.82 
Intra-run % Accuracy 103.59 102.26 99.24 98.02 98.85 
n 18 18 18 18 18 
Inter-run mean±SD 87.047 238.286 1531.780 3488.971 17845.371 
Inter-run±SD 4.52 8.75 83.07 180.36 1035.49 
Inter-run %CV 5.20 3.67 5.42 5.17 5.80 
Inter-run % Accuracy 102.15 99.27 102.11 99.68 101.97 
*Number of each concentration injections-6 
 
Table 5: Recovery 





















n 6 6 6 6 6 6 6 6 
mean±SD 10990 8653 78700 58300 206637 139485 244963 170808 
±SD 395 351 2603 3391 7286 9517 10887 5324 
%CV 3.59 4.06 3.31 5.81 3.53 6.82 4.44 3.12 
% Recovery 78.74 74.08 67.50 69.73 
%Global CV 7.69 - 
%Global recovery 73.44 - 
*Number of injections-6 
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n 6 6 6 6 6 
Intra-run mean±SD 79.260 227.333 1529.991 3583.002 17548.005 
Intra-run±SD 1.58 9.63 71.93 198.80 822.62 
Intra-run %CV 2.00 4.24 4.70 5.55 4.69 
Intra-run % Accuracy 93.02 94.71 101.99 102.37 100.27 
*Number of each concentration injections-6 
 
Table 7: Stability 









LQC 240.030 247.259 5.28 103.01 
HQC 3500.204 3410.719 7.72 97.44 
Freeze-thaw  
Stability 
LQC 240.030 244.894 7.38 102.03 
HQC 3500.204 3515.815 4.45 100.45 
Wet extract 
Stability 
LQC 240.030 238.023 3.36 99.16 
HQC 3500.204 3574.314 5.24 102.12 
Autosampler 
Stability 
LQC 240.030 248.148 4.65 103.38 
HQC 3500.204 3498.503 4.12 99.95 
Long term plasma 
stability 
LQC 240.030 234.321 4.26 97.62 
HQC 3500.204 3565.980 4.72 101.88 
DIQC 17501.022 17115.229 3.86 97.80 
*Number of each concentration injections-6 
 
 
Fig. 2: Extracted LLOQ of brivudine 
 
 
Fig. 3: Extracted ULOQ of brivudine 
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Fig. 4: Calibration curve of brivudine 
 
CONCLUSION 
A simple, accurate, precise, linear and rugged bioanalytical HPLC 
method for the brivudine was developed and validated with 
sofosbuvir used as ISTD. The developed method was validated 
according to the USFDA regulatory guidelines procedure (May-
2018) and all the validation parameters were within the acceptable 
range. Hence, the method can use for application in 
bioavailability/bioequivalence (BA/BE) studies and Therapeutic 
Drug Monitoring (TDM) with desired precision and accuracy along 
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